Show/Hide Menu

MOR106

MOR106 is a human monoclonal IL-17C antibody for the treatment of atopic dermatitis and the 1st Ylanthia-Antibody in clinic

MOR106 is the first publicly disclosed human monoclonal antibody designed to selectively target IL-17C in clinical development worldwide. MOR106 has been shown to potently inhibit the binding of IL-17C to its receptor and thus to inhibit its biological activity. Testing MOR106 in rodent inflammatory skin models of atopic dermatitis and psoriasis supports clinical development of MOR106.

MOR106 arises from a strategic discovery and co-development alliance between Galapagos and MorphoSys, in which both companies contribute their core technologies and expertise. Galapagos provides the disease-related biology including cellular assays and targets discovered using its target discovery platform. MorphoSys contributes its Ylanthia antibody technology to generate fully human antibodies directed against the target and contributes full CMC development of this compound.

Mode of Action

Clinical Studies

MOR106 is currently being investigated in a clinical phase 1 study to evaluate the safety, tolerability and pharmacokinetics in healthy volunteers and in patients with moderate to severe atopic dermatitis. Here you can find further information on the active clinical trial.

Background

MorphoSys and Galapagos entered a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in 2008. Here you can find the corresponding press release explaining the inital launch of the collaboration.